Sun Pharma officially gets its moment of glory. The Indian giant has shed its label as a “low-cost provider” to strategically pivot towards high value-added specialty products. Despite some regulatory obstacles and sustained R&D expenses, the strategy is clearly bearing fruit.
“The pharmacy of the world” demonstrated impressive resilience in 2025. The Indian pharmaceutical industry reached a record turnover of 4,720 billion Indian rupees, approximately $50.5 billion.
For the first time ever, exports rose to $30.47 billion, up 9.4% from the previous year’s $27.85 billion, according to the Indian Ministry of Commerce and Industry. The United States remains the top customer, absorbing nearly $9 billion in exports, with a massive market share of 14.29%.
As the global market is expected to grow from $1.6 trillion to $2.3 trillion by 2030 according to a Grand View Research report, India is quickly moving away from its role as a simple supplier of cheap generics.
Leading the way is Sun Pharmaceutical Industries Ltd, a national titan that has been reinventing itself. The company spent the year transforming into a global leader in specialty products, setting the pace for the future of healthcare in India. This shift resulted in double-digit profit growth for the fiscal year.
Financial results improvement
Sun Pharma generated a total revenue of INR 520.4 billion, a 9% increase from the INR 477.6 billion recorded in the 2024 fiscal year. The net profit was even more impressive, with an adjusted net profit reaching INR 119.8 billion, a 19% year-on-year increase. This momentum was fueled by its Global Specialty division, which emerged as a major growth driver.
The Indian domestic market remains dominant, accounting for 33% of total revenue. Sales reached INR 169.2 billion, up 13.7% from the previous year’s INR 148.9 billion. Business in the United States contributed 31% to the mix, with sales of INR 162.4 billion, showing a steady 3.6% year-on-year growth.
Ilumya, the company’s drug used to treat moderate to severe plaque psoriasis in adults, brought in $681 million in global sales for the 2025 fiscal year. Additionally, the active pharmaceutical ingredients (API) segment and other revenues increased by 11% year-on-year to reach INR 21.29 billion.
A growth potion
Sun Pharma followed through on its R&D commitments in the 2025 fiscal year. The company invested INR 32.48 billion in its laboratories, a steady 2.2% increase from the INR 31.78 billion spent in 2024.
About 40% of the total R&D budget was dedicated to the Global Specialty division and the innovation pipeline. Sun Pharma currently has 116 abbreviated new drug applications (ANDA) and 14 new drug applications (NDA) awaiting approval from the US FDA. Despite this massive investment in future innovation, the company’s recent stock performance has slightly slowed from its historical highs.
Potential upside?
Trading at INR 1,652.20, the stock has actually declined by about 3.1% over the past 12 months, moving away from its 52-week high of INR 1,851.20. Although the market capitalization reaches the staggering figure of INR 3.9 trillion ($42.4 billion), the valuation seems surprisingly moderate.
With an average target price of INR 1,956.28, an 18% upside potential is achievable; some analysts even believe it could soar by 44% to reach INR 2,392.00. Trading at 34.1 times its projected earnings for the 2026 fiscal year, the stock is slightly cheaper than its three-year average of 35.5 times.
Moreover, market specialists are optimistic: out of 36 analysts covering the stock, 32 have issued a buy recommendation.
Possible side effects
The new American reciprocal tariffs of 26% are a real headache. As Sun Pharma heavily relies on patented specialty drugs like Ilumya, it is much more exposed to these costs than its peers focused on generics. Persistent rumors suggest a potential $12 billion deal for American company Organon & Co., although management has officially described this information as “speculative.” Incurring such debt – on top of Organon’s existing $8.9 billion liabilities – could disrupt Sun’s conservative management reputation and cash reserves.
Adding to that the ongoing compliance challenges with the USFDA in manufacturing facilities, the journey ahead could prove to be tumultuous.
